High Squeeze Risk for INO
Inovio Pharmaceuticals (INO) is currently flagged with a high short squeeze score of 97/100, according to data from Tapeboard. With 22.2% of its float currently sold short and a significant borrow fee of 24.1%, the stock is exhibiting classic signs of a potential squeeze setup.
Market Dynamics
Short sellers are paying a premium to maintain their positions, as evidenced by the elevated borrow fee. The combination of high short interest and a high squeeze score suggests that the stock is sensitive to upward price momentum. Traders should monitor the stock for any signs of a breakout, as the high cost of borrowing may force some short sellers to cover their positions if the price continues to climb.
Signal data sourced from Tapeboard. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.